Crescendo Biologics Ltd.
🇳🇿New Zealand
- Country
- 🇳🇿New Zealand
- Ownership
- Holding
- Established
- 2007-01-01
- Employees
- 51
- Market Cap
- -
Clinical Trials
2
Active:1
Completed:0
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)A Phase I Study to Assess PSMA+ and PSMA- Tumour Lesions
Phase 1
Active, not recruiting
- Conditions
- Advanced and/or Metastatic Solid Tumours
- Interventions
- Drug: Radiolabelled CB307
- First Posted Date
- 2023-05-01
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Crescendo Biologics Ltd.
- Target Recruit Count
- 5
- Registration Number
- NCT05836623
- Locations
- 🇳🇱
University Medical Center Groningen,, Groningen, Netherlands
Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours.
- First Posted Date
- 2021-04-09
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Crescendo Biologics Ltd.
- Target Recruit Count
- 70
- Registration Number
- NCT04839991
- Locations
- 🇺🇸
University of Washington, Seattle, Washington, United States
🇳🇱Antoni van Leeuwenhoek, Amsterdam, Noord-Holland, Netherlands
🇳🇱VUMC Research B.V, Amsterdam, Noord-Holland, Netherlands
News
No news found